264 related articles for article (PubMed ID: 19887280)
21. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
22. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
23. [Monitoring of neuromuscular block and prevention of residual paralysis].
Fuchs-Buder T; Meistelman C
Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S46-50. PubMed ID: 19887277
[TBL] [Abstract][Full Text] [Related]
24. Sugammadex: A Review of Neuromuscular Blockade Reversal.
Keating GM
Drugs; 2016 Jul; 76(10):1041-52. PubMed ID: 27324403
[TBL] [Abstract][Full Text] [Related]
25. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
Della Rocca G; Pompei L; Pagan DE Paganis C; Tesoro S; Mendola C; Boninsegni P; Tempia A; Manstretta S; Zamidei L; Gratarola A; Murabito P; Fuggiano L; DI Marco P
Acta Anaesthesiol Scand; 2013 Oct; 57(9):1138-45. PubMed ID: 23849107
[TBL] [Abstract][Full Text] [Related]
26. The concept behind sugammadex.
Epemolu O; Bom A
Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
[TBL] [Abstract][Full Text] [Related]
27. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
Blobner M; Eriksson LI; Scholz J; Motsch J; Della Rocca G; Prins ME
Eur J Anaesthesiol; 2010 Oct; 27(10):874-81. PubMed ID: 20683334
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients].
Takeda J; Iwasaki H; Otagiri T; Katoh T; Shingu K; Obara H; Nakatsuka H; Tomiyama Y; Kasaba T
Masui; 2014 Oct; 63(10):1083-8. PubMed ID: 25693333
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
Lee C; Katz RL
J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
[TBL] [Abstract][Full Text] [Related]
30. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
Mosing M; Auer U; West E; Jones RS; Hunter JM
Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
[TBL] [Abstract][Full Text] [Related]
31. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
Ren WH; Jahr JS
Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
[TBL] [Abstract][Full Text] [Related]
32. [Problem of neuromuscular block reversion: neostigmine and sugammadex].
Mizikov VM; Stamov VI; Deshko IuV; Ialich AIu
Anesteziol Reanimatol; 2010; (2):40-3. PubMed ID: 20524330
[TBL] [Abstract][Full Text] [Related]
33. Sugammadex in anesthesia practice.
Duvaldestin P; Plaud B
Expert Opin Pharmacother; 2010 Nov; 11(16):2759-71. PubMed ID: 20977408
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex.
Martinez-Ubieto J; Ortega-Lucea S; Pascual-Bellosta A; Arazo-Iglesias I; Gil-Bona J; Jimenez-Bernardó T; Muñoz-Rodriguez L
Minerva Anestesiol; 2016 Jul; 82(7):735-42. PubMed ID: 26472231
[TBL] [Abstract][Full Text] [Related]
35. Sugammadex: a review of its use in anaesthetic practice.
Yang LP; Keam SJ
Drugs; 2009; 69(7):919-42. PubMed ID: 19441874
[TBL] [Abstract][Full Text] [Related]
36. Operating room discharge after deep neuromuscular block reversed with sugammadex compared with shallow block reversed with neostigmine: a randomized controlled trial.
Putz L; Dransart C; Jamart J; Marotta ML; Delnooz G; Dubois PE
J Clin Anesth; 2016 Dec; 35():107-113. PubMed ID: 27871505
[TBL] [Abstract][Full Text] [Related]
37. Preclinical pharmacology of sugammadex.
Bom A; Hope F; Rutherford S; Thomson K
J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
[TBL] [Abstract][Full Text] [Related]
38. Sugammadex: the first selective binding reversal agent for neuromuscular block.
Kovac AL
J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of sugammadex.
Caldwell JE; Miller RD
Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
[TBL] [Abstract][Full Text] [Related]
40. Sugammadex approved to reverse NMBA effects.
Thompson CA
Am J Health Syst Pharm; 2016 Feb; 73(3):100. PubMed ID: 26796899
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
